{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:56:42Z","timestamp":1790690202832,"version":"4.1.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Classical Hodgkin lymphoma (cHL) is an unusual B-cell\u2013derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an extensive but ineffective inflammatory\/immune cell infiltrate. This striking feature suggests that malignant HRS cells escape immunosurveillance and interact with immune cells in the cancer microenvironment for survival and growth. We previously found that cHLs have a genetic basis for immune evasion: near-uniform copy number alterations of chromosome 9p24.1 and the associated PD-1 ligand loci, CD274\/PD-L1 and PDCD1LG2\/PD-L2, and copy number\u2013dependent increased expression of these ligands. HRS cells expressing PD-1 ligands are thought to engage PD-1 receptor\u2013positive immune effectors in the tumor microenvironment and induce PD-1 signaling and associated immune evasion. The genetic bases of enhanced PD-1 signaling in cHL make these tumors uniquely sensitive to PD-1 blockade.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.310","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"310-316","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"2017","author":[{"given":"W. Robert","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111705580608500_B1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.seminhematol.2016.05.007","article-title":"Hodgkin lymphoma: pathology and biology","volume":"53","author":"Mathas","year":"2016","journal-title":"Semin Hematol"},{"issue":"12","key":"2019111705580608500_B2","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111705580608500_B3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ijc.23119","article-title":"Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5\/Rantes in tumor cell growth and microenvironmental interactions","volume":"122","author":"Aldinucci","year":"2008","journal-title":"Int J Cancer"},{"issue":"2","key":"2019111705580608500_B4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.11370","article-title":"Expression of CCL5\/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue","volume":"107","author":"Fischer","year":"2003","journal-title":"Int J Cancer"},{"issue":"11","key":"2019111705580608500_B5","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","article-title":"Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege","volume":"66","author":"Ishida","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"2019111705580608500_B6","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"issue":"7247","key":"2019111705580608500_B7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nature07969","article-title":"Frequent inactivation of A20 in B-cell lymphomas","volume":"459","author":"Kato","year":"2009","journal-title":"Nature"},{"issue":"5","key":"2019111705580608500_B8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J Exp Med"},{"issue":"3","key":"2019111705580608500_B9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"key":"2019111705580608500_B10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-\u03baB deregulation in Hodgkin lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"2019111705580608500_B11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1084\/jem.20020062","article-title":"Nuclear factor kappaB-dependent gene expression profiling of Hodgkin\u2019s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity","volume":"196","author":"Hinz","year":"2002","journal-title":"J Exp Med"},{"issue":"2","key":"2019111705580608500_B12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood.V99.2.618","article-title":"Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019111705580608500_B13","first-page":"549","article-title":"Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells","volume":"60","author":"Joos","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"2019111705580608500_B14","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"issue":"4","key":"2019111705580608500_B15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.2900","article-title":"Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma","volume":"46","author":"Gunawardana","year":"2014","journal-title":"Nat Genet"},{"issue":"15","key":"2019111705580608500_B16","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J"},{"issue":"4","key":"2019111705580608500_B17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/leu.2011.265","article-title":"Notch is an essential upstream regulator of NF-\u03baB and is relevant for survival of Hodgkin and Reed-Sternberg cells","volume":"26","author":"Schwarzer","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2019111705580608500_B18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin\u2019s lymphoma cells through a mechanism involving Akt kinase and mTOR","volume":"205","author":"Dutton","year":"2005","journal-title":"J Pathol"},{"issue":"3","key":"2019111705580608500_B19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood-2002-11-3507","article-title":"MEK\/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival","volume":"102","author":"Zheng","year":"2003","journal-title":"Blood"},{"key":"2019111705580608500_B20","doi-asserted-by":"crossref","first-page":"35745","DOI":"10.1038\/srep35745","article-title":"Dual PI3K\/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation","volume":"6","author":"Locatelli","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"2019111705580608500_B21","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3K\u03b4 inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Meadows","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111705580608500_B22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"7338","key":"2019111705580608500_B23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"9","key":"2019111705580608500_B24","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111705580608500_B25","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/0008-5472.CAN-05-3252","article-title":"Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin\u2019s lymphoma","volume":"66","author":"Chemnitz","year":"2006","journal-title":"Cancer Res"},{"issue":"32","key":"2019111705580608500_B26","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1073\/pnas.0706017104","article-title":"The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma","volume":"104","author":"Juszczynski","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"2019111705580608500_B27","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2012-12-474569","article-title":"Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma","volume":"121","author":"Ouyang","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111705580608500_B28","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"issue":"17","key":"2019111705580608500_B29","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111705580608500_B30","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111705580608500_B31","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"2019111705580608500_B32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"2019111705580608500_B33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"issue":"7655","key":"2019111705580608500_B34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"2","key":"2019111705580608500_B35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"issue":"6","key":"2019111705580608500_B36","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"issue":"1","key":"2019111705580608500_B37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"2019111705580608500_B38","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"issue":"6332","key":"2019111705580608500_B39","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"issue":"6332","key":"2019111705580608500_B40","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"issue":"6","key":"2019111705580608500_B41","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"6","key":"2019111705580608500_B42","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111705580608500_B43","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2019111705580608500_B44","article-title":"Topological analysis reveals a PD-L1 associated immuno-pretective niche for Reed-Sternberg cells in Hodgkin lymphoma [published online ahead of print 11 September 2017]","author":"Carey","journal-title":"Blood"},{"issue":"16","key":"2019111705580608500_B45","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","article-title":"How I treat relapsed and refractory Hodgkin lymphoma","volume":"117","author":"Kuruvilla","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111705580608500_B46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111705580608500_B47","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"2019111705580608500_B48","first-page":"JCO673467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure [published online ahead of print]","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111705580608500_B49","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111705580608500_B50","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class i expression is associated with inferior outcome independent of 9p24.1 Status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2019111705580608500_B51","doi-asserted-by":"crossref","first-page":"e1295202","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy?","volume":"6","author":"Nijland","year":"2017","journal-title":"OncoImmunology"},{"issue":"7528","key":"2019111705580608500_B52","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"7620","key":"2019111705580608500_B53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"2019111705580608500_B54","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"issue":"7549","key":"2019111705580608500_B55","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2019111705580608500_B56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"21","author":"Linnemann","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"2019111705580608500_B57","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2019111705580608500_B58","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111705580608500_B59","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111705580608500_B60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/310\/1250701\/hem00043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/310\/1250701\/hem00043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T05:58:36Z","timestamp":1573970316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/310\/21170\/Signaling-pathways-and-immune-evasion-mechanisms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.310","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}